VIRONGY, LLC

Biotech · Private

Rev-A3R5 reporter cell line for HIV broadly neutralizing antibody detection and quantification

Grants
$217K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Hiv Rev-dependent Reporter Cell For Neutralizing Antibody Discovery$216,675
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2145ISOLERE BIO INC——
2146Origin Life Sciences, Inc.—$2.9M
2147KALION, INC.—$6.7M
2148VIRONGY, LLC——
2149EpiBiologics, Inc.—$30M
2150Egalet Corp—$42M
2151Denali Medical II, Inc.—$4.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Lim Kinase Inhibitorsapplication
  • Lim Kinase Inhibitorsapplication
  • Actin-based Peptidesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.